We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Santarus, Inc. (MM) | NASDAQ:SNTS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 31.97 | 0 | 01:00:00 |
Durata Therapeutics, Inc. (DRTX) continues to progress with its lead candidate, dalbavancin, which is being developed for the treatment of patients with complicated skin and soft tissue infections (cSSTI).
Earlier this month, Durata submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for dalbavancin seeking approval for the marketing and sale of dalbavancin for the treatment of patients with cSSTI.
Durata recently announced that its MAA has been accepted for review by the EMA. Durata expects a decision by the first half of 2015.
The MAA was submitted based on positive results from three phase III trials – DISCOVER 1, DISCOVER 2 and VER001-9.
The data from DISCOVER 1 and DISCOVER 2 indicated that dalbavancin achieved its primary efficacy endpoint of non-inferiority of clinical response at 48 to 72 hours after initiation of therapy. Dalbavacin also achieved its secondary endpoint, which was clinical success at the end of treatment.
We remind investors that the U.S. Food and Drug Administration (FDA) accepted Durata’s New Drug Application (NDA) for Dalvance (dalbavancin) for priority review in Nov 2013.
Durata is seeking FDA approval of Dalvance for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive microorganisms, including MRSA (methicillin resistant Staphylococcus aureus). A decision by the FDA is expected by May 26, 2014.
Durata currently does not have any marketed product in its portfolio. Hence, the successful development and commercialization of dalbavancin will be a big boost to the company’s portfolio.
Durata currently carries a Zacks Rank #3 (Hold). Better-ranked stocks include Forest Laboratories (FRX), Santarus Inc. (SNTS) and Jazz Pharmaceuticals (JAZZ), all with a Zacks Rank #1 (Strong Buy).
1 Year Santarus Chart |
1 Month Santarus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
